Sarepta Therapeutics | SRPT - Current Liabilities


Sarepta Therapeutics reported $499.16M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 24.96B 534M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Capricor Therapeutics USD 33.64M 2.2M Mar/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026